Clinigen’s value proposition is fairly straightforward. Clinigen expands and extends the true value of a pharma or biotech partner’s product’s lifecycle
In Conversation
"The most important challenge that Turkey’s healthcare system faces, especially in the private sector, is financing"
"Despite the size of the market in Portugal, the affiliate has to make the right decisions to keep our financial key performance indicators healthy."
"While we may not yet be feeling the effects of falsified medicines right now in Spain, I think that, if mitigating steps are not taken, then…
"There is vast potential in healthcare, and the data is so massive—far more significant than banking or telecommunications— that we need help in harnessing the potential…
"As we make our own products, we focus on our core technologies. Yet, we still partner with a lot of companies, whether in hardware, hospital information…
"Teva is recognized by the Portuguese government as an ideal partner in this area, as we offer the right balance between accessibility and innovation. Therefore, we…
"In Spain, it is widely perceived that the hospitals are stuck in their mindset because although we have some of the best healthcare institutes in the…
". Inevitably, we had to make some concessions in our policy here, but Takeda’s global strategy is to implement a responsible pricing plan because we want…
"We have a good track record in this regard – and ‘Made in Shenzhen’ products are recognized within China as representing better quality and bringing value…
In recent years we have refocused our efforts and invested heavily in the UK—our new global headquarters in Cambridge is just one example— and we want…
"We can already feel that TITCK’s improvements have had a positive impact on the Turkish ecosystem at large and could usher in evermore-promising outcomes for the…
